https://www.selleckchem.com/products/etc-159.html
There is no consensus on the management of the coronavirus disease (COVID-19) in patients with secondary immunosuppression due to either an underlying haematological disease or to the effects of immunochemotherapy (ICT). Some of them may present persistent infection with multiple relapses of the COVID-19, requiring several admissions. This study evaluated the clinical characteristics and outcomes after treatment of five patients with follicular lymphoma (FL), previously treated with ICT, who developed several episodes of COVID-19. We an
Curtir
Comentario
Compartilhar
